Chewing gum with tomatidine

Abstract
A chewing gum with a liquid-fill composition and a surrounding gum region, with one or both containing active ingredients, such as herbal, medicinal and/or mineral elements or combinations thereof, present in an amount of at least about 0.05 mg.
Description
FIELD OF THE INVENTION

The present invention is directed to functional gums, suckers (e.g., lollipops) and lozenges, and more particularly, to a gum and/or sucker and/or lozenge that has at least an exterior and an interior component, having distinct metabolic and functional characteristics that correspond with the ingredients contained therein.


BACKGROUND OF THE INVENTION

Throughout the ages, human beings have attempted to attain and maintain particular body morphologies, and in particular, have attempted to control their weight so as to conform with then-fashionable mores. During the recent past, a preference for less massive morphologies has been in vogue and a populous genetically ill-equipped to conform with such weight characteristics is bombarded with images of svelte figures in both male and female forms.


The desire of individuals to lose weight and specifically, to lose fatty tissue, has become nearly an obsession in the United States and many other countries. Any simple and safe method toward achieving a slim figure is in great demand. Methods for losing weight include hundreds of advised diets, machines and methods for exercise, various psychiatric techniques involving alteration in mental attitudes, and a variety of surgical techniques. Liposuction has created an entirely new surgical cosmetic industry, but carries a small but significant risk and often leaves the patient with an unsightly cosmetic result due to the inflammatory reaction surrounding where the fatty tissue has been removed by a technique which produces a severe tissue reaction.


Obesity is a serious public health hazard, second in importance only to tobacco. Approximately ⅓ of Americans are seriously overweight according to life insurance data. In approximately 12 million Americans, obesity significantly contributes toward the cause and complications of serious disease. Such conditions include heart and lung disease, many types of cancer, diabetes, high blood pressure, and peripheral arterial disease. This is in addition to how obesity becomes a cosmetic problem. Being overly fat limits both length of life and its quality.


A multi-billion dollar industry has developed in an effort to control weight. The many varied and expensive techniques employed speak to the relative ineffectiveness of the many techniques that have been tried to get rid of excess fat.


Obesity has recently been recognized as a public health hazard of epidemic proportions by the World Health Organization. One of three Americans between the ages of 20-74 are obese (Body Mass Index>30 Kg/m2 body surface). This amounts to 58 million people. The number of obese adults has increased dramatically. In 1980 25% of US adults were obese. The equivalent figure was 33% in 1990. In Europe the equivalent figure is about 40%.


Obesity significantly contributes to the dangers of other diseases in approximately half of those who exceed the threshold description of obesity. For example, 19% of the cost of management of heart disease can be ascribed to obesity. Obesity is also recognized as a co-morbid factor for obese patients suffering from degenerative arthritis, peripheral vascular disease, and many forms of pulmonary disease such as emphysema. The expenditure for products, goods, and services in the management of obesity is estimated to be $33 billion per year. This is 3%-4% of total health care expenditure per year and exceeds that expended for AIDS and cancer.


Obesity is such a prevalent, important and distressing problem that its many methods for suggested management are too well known to deserve more than listing. They include diets that exclude fats and high caloric elements, food supplements, appetite suppressants, exercise machines and regimes, biofeedback and other psychotherapeutic techniques, and a variety of operative techniques. Operations include a number of methods for decreasing the capacity the stomach, gastric by-pass operations, methods to shorten the small intestinal absorption surface, excision of the unwanted fat (lipectomy) and techniques of liposuction. Liposuction is performed approximately 51,000 times each year in the US. The maximum amount of fat that can safely be removed is approximately 2 Kg. Being an operative technique for removing fat, in this case by suction, it inevitably excites an inflammatory response at the operative site, which results not only in post operative inflammation but in subsequent uneven and unsightly scarring beneath the skin where the fat has been removed.


Incorporated by reference in its entirety are the following U.S. patents directed generally to chewing gum compositions, methods and apparatus for making chewing gum, and in particular, methods for enabling one of skill in the art to produce soft-centered chewing gums as contemplated by the present invention. The novelty of the present invention, however, should be understood as being distinguished from such prior art references and such incorporation by reference is only provided for enabling support of the numerous ways in which the particular novel product can be manufactured. The U.S. patents incorporated by reference are as follows: U.S. Pat. Nos. 5,922,347; 5,916,606; 5,912,030; 5,900,230; 5,885,630; 5,866,179; 5,858,423; 5,846,557; 5,834,002; 5,827,526; 5,824,291; 5,736,175; 4,156,740; 5,498,429; 4,466,983; 4,157,402; 5,569,477; 5,125,819; 5,248,508; 4,975,288; 4,792,453; 4,980,178; 4,683,138; 5,087,460; 4,292,329; 4,642,235; 4,316,915; 4,513,012; 4,250,196; 5,431,929; and 4,647,450.


Weight control systems and methods have improved over the years. Indeed, the ancient Romans believed that the vomitorium was penance for their uncontrollable feasting and drinking during long celebrations for their various deities. Modern methods of weight control including arduous and sometimes bizarre workout routines and machines are no less peculiar in modern times. Moreover, with the advent of liposuction, stomach stapling, etc., there appears to be no bounds beyond which humans will go to attain desired physical characteristics as such relate to their weight. The effect of such weight norms has created a $60 billion a year market for diet and weight control products. It is estimated that nearly half of all American women, and a quarter of all men, are on a diet at any given time. As is well known, however, most diets, studies have shown, do not work for nine out of ten people who, after suffering through such diets, quickly regain their weight and often exceed their previous body mass. Such an unfortunate volley of feasting and dieting leads not only to physical harm due to increased rates of diabetes, arterial sclerosis, and other physical health problems, but also to an often devastating decreased estimation of a person's self-worth.


There is thus a long felt but unsolved need for an effective, inexpensive and easy way in which to provide health conscious individuals with diet products to assist in achieving desired weight loss.


SUMMARY OF THE INVENTION

In one embodiment, the present invention is directed to a method and product which provides functional components such as, herbal, medicinal and/or vitamin substances for various applications (e.g., weight control substances) to an individual other than through the consumption of pills, suppositories, diet beverages and/or tasteless and low caloric foodstuffs. In one embodiment, the present invention is directed to a particular gum product having at its center a composition different from the surrounding gum and having distinct functional and metabolic characteristics. For example, various metabolism increasing components can be provided in the interior of a gum in a liquid or semi-liquid form while the gum itself can be of a traditional gum composition and/or may incorporate various other desirable metabolic increasing components to supplement and/or coact with components contained in the liquid center of the gum. Indeed, in one particular embodiment of the present invention, time release capsules may be provided suspended in a liquid medium inside a gum enclosure.


The present discussion pertains principally to a diet control gum/lozenge/lollipop, but the present invention is not so limited and includes one or more combinations of ingredients as set forth, for example, in Tables I and II below, which may be useful in numerous and varied applications. For illustration purposes only, however, the following discusses weight loss applications of the present invention. In one embodiment, chewing of the gum-based product releases the interior liquid substance, thus providing a product and a method desirable by weight conscious individuals who do not wish to publicly announce or disclose their dietary desires. In a preferred embodiment, the substance contained within the gum (e.g. the interior liquid substance) would have as a principal characteristic the capability of increasing a user's caloric burn rate (e.g. by increasing a person's metabolism, adjusting/regulating hormonal activity in an individual, providing fiber to increase a person's feelings of satiety).


In a particular embodiment of the present invention, a gum is utilized having liquid interior components surrounded by the dense gum, for example, the interior having a density less than 10% as dense as the exterior gum, more preferably at least about 15% less dense, and more preferably, at least about 35% less dense than the surrounding gum. The interior liquid components can be herbal, organic, natural, chemical and/or hormonal in nature, and may be selected dependent upon their individual and synergistic characteristics, with the objective being to increase a person's metabolism in order to achieve a higher caloric burn rate and/or to decrease the desire for additional food (e.g. generate a feeling of satiety or fullness). It is within the scope of the present invention to incorporate various known diet control substances in either the gum material itself and/or in the liquid interior material encompassed by the gum material. In a preferred embodiment, however, the surrounding gum material is comprised of traditional gum flavors and compositions and the interior liquid and/or semi-liquid (e.g. gel) components of the present invention comprise diet regulating substances.


Yet another embodiment of the present invention relates to a hard candy substance (e.g. primarily comprising a natural sugar and corn syrup base) often referred to as a “sucker” or “lollipop.” The interior of the sucker or lollipop, however, contains a less rigid, soft and/or liquid or semi-liquid component. The enclosed material of the lollipop includes metabolic enhancers for weight and caloric control.


In still another embodiment, a lozenge can be manufactured having a denser exterior and a less dense interior, where either the interior or exterior of the lozenge, or both, contain diet controlling substances. Preferably, diet controlling substances are positioned within the interior of such lozenges so as to facilitate the enjoyment by an individual of consuming the lozenge without the possible unpleasant and/or undesirable taste characteristics of various dietary components within the center of the lozenge.


It will be understood that one purpose of certain embodiments of the present invention is to increase metabolic efficiency and to burn calories in an individual. Herbal additives may be incorporated into such products to aid in the body's ability to digest food and/or to block absorption of fat molecules into the system. For example, chitosan compositions can be utilized either in the interior and/or exterior of the gum, lollipop and lozenge embodiments desired above and hereafter. In addition to chitosan, other fiber-like components, vitamins and minerals (e.g., especially calcium compositions to treat osteoporosis) can be incorporated into the present invention to provide desired feelings of satiety or fullness to an individual using such products and/or to treat various vitamin and/or mineral deficiencies.


While the present invention is primarily directed to administering diet control substances to individuals, it should be understood that other medicinal and/or nutritional and/or biological components can be administered to animals in general (companion pets, livestock, etc.) but preferably humans. Indeed, the present inventor believes that the administration of medicinal compounds to young children can be greatly facilitated by use of the present invention given that children are more apt to take medicine in the form of a lollipop, lozenge or gum, particularly if the taste and flavor and textural characteristics of such candy products are preserved and effective amounts of desired components are delivered to such individuals when consuming such products.


Muscle atrophy, or wasting, is caused by aging and a variety of illnesses and injuries, including cancer, heart failure, and orthopedic injuries. It makes people weak and fatigued, impairs physical activity and quality of life, and predisposes people to falls and fractures. The condition affects more than 50 million Americans annually, including 30 million people over age 60, and often forces people into nursing homes or rehabilitation facilities. Skeletal muscle atrophy is a common and debilitating condition that lacks an effective therapy. Although skeletal muscle atrophy has broad clinical impact, current treatment recommendations (e.g. physical rehabilitation, nutritional optimization, and treatment of underlying disease) are often ineffective and/or unfeasible. Moreover, a pharmacologic therapy does not exist. Thus, skeletal muscle atrophy represents a very large unmet medical need.


A natural small molecule from tomato plants, tomatidine, is believed to cause cell growth, especially in skeletal muscle tissue. Properly administered, such as via the methods and systems set forth herein, tomatidine is an effective agent to treat muscle atrophy and to further increase strength and exercise capacity. Tomatidine is an inhibitor of muscle atrophy and thus has a use as a therapeutic agent for skeletal muscle atrophy. Tomatidine is a steroidal alkaloid and the aglycone of α-tomatine, an abundant glycoalkaloid in tomato plants that mediates plant defense against fungi, bacteria, viruses and predatory insects. When consumed by animals, α-tomatine is hydrolyzed by stomach acid and intestinal bacteria to tomatidine, which is absorbed by the gut. Tomatidine's effects on skeletal muscle are unknown. However, the finding that the mRNA expression signature of tomatidine negatively correlated to signatures of muscle atrophy suggest that tomatidine has an anti-atrophic (anabolic) effect in skeletal muscle.


In one embodiment, a person having from one, preferably two, and more preferably three pieces of center-filled chewing gum in a 24 hour period of time, such gum containing tomatidine, is able to achieve the stimulation of skeletal muscle anabolism, leading to muscle hypertrophy, increased strength and improved exercise capacity. In still other embodiments, especially those including one or more of the agents as set forth in Tables I and II, and especially at least one metabolic enhancer, tomatidine provided in at least a 1 mg per piece of gum, is believed to result in two major effects on body composition, namely, increased skeletal muscle and decreased fat. Tomatidine is believed to limit the progression of skeletal muscle atrophy during fasting and muscle disuse, and enhances the recovery from disuse skeletal muscle atrophy. Tomatidine and/or α-tomatine are also important components in various embodiments of the present invention directed to inclusion into so-called functional foods and nutraceuticals designed to maintain muscle mass and function in persons without muscle atrophy. In addition to having potential utility in its own right, tomatidine supports the concept that systems-based methods can be used to discover small molecules that improve skeletal muscle mass, function and metabolism. Such compounds could potentially have several beneficial uses for patients and society in general.


Studies have shown that tomatidine fed mice had larger muscles, but their overall body weight did not change due to a corresponding loss of fat. Thus, another aspect of the present invention directed to treating obesity, is further enhanced by providing certain amounts of tomatidine as an effective compound in the treatment of obesity. Tomatidine is a natural compound derived from tomatoes and is produced when alpha-tomatine, which is found in green tomatoes, is digested in the gut. Tomatidine is significantly more potent than ursolic acid in building muscle tissue and has a different mechanism of action. One application of the present invention is to provide a center-filled chewing gum lollipop or lozenge that contains tomatidine, as well as other select agents (set forth herein) in a manner that is effective to preserve muscle mass and function during the aging process. Preferably, the compositions included in the gum center-fill or in the gum base material contain tomatidine without any ursolic acid.


As set forth in Tables I and II below, certain embodiments of the present invention are directed to a center-filled gum, lozenge or lollipop that includes particular combinations of active ingredients, including calcium, vitamin E and a chemotherapeutic agent and/or Herbal component, which in certain embodiments consists of tomatidine. Incorporated herein by this reference are the following US patent publications, which further demonstrate that tomatidine falls into such classifications set forth in Tables I and II herein, i.e. US Patent Publication Nos. 20140030332 to Baron, et. al., and 20070123448 to Kaplan et al.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 represents one embodiment of the invention depicting both a gum-based outer shell and a liquid or syrup center, both consisting of all or some ingredients listed in Table I or Table II.



FIG. 2 represents another embodiment of the present invention in a lollipop form.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The following table contains a list of possible components that may be incorporated into the center of the gum, lollipop and lozenge aspects of the present invention:












TABLE I









Dexatrim
Diuretics



Chitosan
Antacids



Oatmeal fiber
Antibiotics



Vitamins
Herbal components



Mineral supplements
Stimulants



Medicinal components
Metabolic enhancers



Lipid substances (HDLs)



Chemotherapeutic agents










The following U.S. issued patents are also incorporated herein by reference: U.S. Pat. No. 5,474,989 by Hasimoto et al., U.S. Pat. No. 5,747,475 by Norquist et al., U.S. Pat. No. 5,830,883 by Block et al., U.S. Pat. No. 5,880,109 by Nakamura et al., U.S. Pat. No. 4,963,367 by Ecanow, U.S. Pat. No. 4,738,850 by Thakur et al., U.S. Pat. No. 5,846,952 by Vournakis et al., and U.S. Pat. No. 4,223,023 by Furda. It will therefore be appreciated by one of skill in the art that various compositions, formulations, masking agents (e.g., to “mask” unpleasant flavors and/or textures and/or mouth feel characteristics of vitamins, medicinal compounds, minerals, etc.) and binders can be combined with the present structure of the present invention to achieve various desired purposes. For example, controlled release formulations are encompassed by the present invention as are the preparation and use of various different carrier vehicles useful for medicinally administering compositions to animals, time release formulations, compositions having desirable solubility and dissolution rates, and the incorporation into the present invention of food additives such as vitamins, pharmaceutical preparations and other compounds, specifically those that reduce the absorption of lipids such a chitosan.


Both the gum with liquid-type fillers and the sucker with a gum-based center can be comprised of one or more of the following: xanthan, guar, locust bean gum, karaya, gum tragacanth, carrageenans, alginates, gum arabic, corn syrup, sugar, starches, gum bases. While multiple recipes exist, most candy substances can also be made from natural and herbal substitutes listed in Table II. The cavities that are extruded in both the gum and the lollipop can be made with one or more cavities that can be filled with multiple bio-enhancing and weight management substances, compiling all or some of the properties in Table II. The combination of them will achieve various results. Example: Guarana and malluang and chitosan will create energy and a feeling of “fullness” for the consumer; chromium picolinate (RE. 33, 988) and ginseng and ginger will allow the user to burn calories more efficiently).












TABLE II









Siberian Ginseng
Vitamin E



Green Tea
Zinc



Casgara Sagrada
Mahuang



Apple Pectin

Astragalus




Dandelion
Guarana



Chickweek
Bee Pollen




Gymnema Sylvestre

Chromium Picolinate



Licorice
Bluegreen Algae



Bladderwrack
Royal Jelly



Ginger
Damiana



Magnesium
Lecithin



Sarsaparilla
Gotu Kola



Golden Seal
Nettles



Chitosan










The amounts of all or some of these ingredients can vary, preferably being present in an amount between no less than about 0.05 mg. The size of the gum exterior can be made of a size less than 4.5 grams to more than 18.4 grams with the cavity center being able to accommodate a volume between 0.5 mg to more than 5 grams. The lollipop can be a total size of less than 0.65 oz. with the cavity center being a volume of no more than 0.42 oz. and no less than 4.5 grams, to a size larger than 1.35 oz. with a cavity center being of at least 19 grams.


In one particular embodiment, the invention is directed to a beverage, so-called a Bloody Mary beverage, that includes the following: in a 12 fluid once serving: up to but not exceeding 9.9% alcohol (by volume); no fat; up to 1200 mg of sodium; 3 grams of protein; Vitamin C, Vitamin A, calcium, potassium and iron. In a preferred embodiment the beverage includes water, tomato concentrate, natural grain spirits, high fructose corn syrup, aloe vera juice, sodium chloride, vinegar, citric acid, taurine, pectin, ascorbic acid, and citrus aurantium extract. In still other embodiments, the beverage includes the following: fresh horseradish, tomato juice, Tabasco, Worcestershire sauce, celery salt, and one of amontillado; cream sherry, and pure cane sugar. In yet another embodiment, the present invention includes a beverage consisting of: water; a tomato concentrate having a tomato soluble solids content of about 24% to about 36% by weight, ethyl alcohol, Vitamin C, Vitamin A, calcium, potassium, iron, water, high fructose corn syrup, aloe vera juice, sodium chloride, vinegar, citric acid, taurine, pectin, ascorbic acid, and citrus aurantium extract, horseradish, Worcestershire sauce, and celery salt. Certain other embodiments are directed to a Bloody Mary beverage that has the benefits of an energy drink, and include at least the following: tomato juice containing lycopene, Ginger, Honey, taurine and caffeine. By way of providing additional background, context, and to further satisfy the written description requirements of 35 U.S.C. §112, the following references are incorporated by reference in their entireties: U.S. Patent Publication No. 20130115329 to Savant, et al. and U.S. Pat. No. 8,202,561 to Livaich. One of skill in the art will further appreciate that the beverage ingredients of the above can also be incorporated into the chewing gum and lollipop embodiments as further described herein.


While various embodiments of the present invention have been described in detail, it is apparent that further modifications and adaptations of the invention will occur to those skilled in the art. However, it is to be expressly understood that such modifications and adaptations are within the spirit and scope of the present invention.

Claims
  • 1. A chewing gum product consisting essentially of a first substance configured so as to have at least one cavity capable of retaining a liquid or semi-liquid substance as a second substance, wherein at least said second substance has an active ingredient consisting essentially of a chemotherapeutic agent and at least one ingredient selected from the group consisting of calcium, zinc, chromium picolinate, magnesium, a metabolic enhancer and combinations thereof, said active ingredient present in an amount of at least about 0.05 mg, wherein said active ingredient is present in the form of a controlled release formulation, and wherein said controlled release formulation comprises time release capsules.
  • 2. A chewing gum product consisting essentially of a first substance configured so as to have at least one cavity capable of retaining a liquid or semi-liquid substance as a second substance, wherein at least said second substance has an active ingredient consisting essentially of a chemotherapeutic agent and at least one ingredient selected from the group consisting of a metabolic enhancer, green tea, zinc, chromium picolinate and magnesium, said active ingredient present in an amount of at least about 0.05 mg, wherein said active ingredient is present in the form of a controlled release formulation, and wherein said controlled release formulation comprises time release capsules.
  • 3. A chewing gum product consisting essentially of a first substance configured so as to have at least one cavity capable of retaining a liquid or semi-liquid substance as a second substance, wherein at least said second substance has an active ingredient consisting essentially of a chemotherapeutic agent, calcium, zinc and magnesium, said active ingredient present in an amount of at least about 0.05 mg, wherein said active ingredient is present in the form of a controlled release formulation, and wherein said controlled release formulation comprises time release capsules.
  • 4. The chewing gum of claim 1 wherein said active ingredient is present in an amount of more than 30 mg.
  • 5. A chewing gum as act forth in claim 1, wherein said controlled release formulation has desirable solubility and dissolution rates.
CROSS REFERENCE TO RELATED APPLICATIONS

This is a continuation-in-part application of pending prior application Ser. No. 14/220,224 filed on Mar. 20, 2014, which is a continuation-in-part of application Ser. No. 12/052,054 filed on Mar. 20, 2008 (now U.S. Pat. No. 8,679,522), which is a continuation of application Ser. No. 11/084,707 filed on Mar. 17, 2005 (now U.S. Pat. No. 7,351,425), which is a continuation of prior application Ser. No. 10/646,503 filed on Aug. 21, 2003 (now U.S. Pat. No. 6,869,614), which is a continuation of application Ser. No. 10/316,700 filed on Dec. 10, 2002 (now U.S. Pat. No. 6,652,839), which is a continuation of application Ser. No. 09/664,630 filed on Sep. 19, 2000 (now U.S. Pat. No. 6,491,540) and claims priority from U.S. Provisional Patent Application No. 60/154,972 filed on Sep. 20, 1999. The entire disclosure of the prior applications are considered to be part of the disclosure of the accompanying application and are hereby incorporated by reference.

US Referenced Citations (258)
Number Name Date Kind
1298670 Cramer Apr 1919 A
1629461 Berg et al. May 1927 A
2892753 Schmidt et al. Jun 1959 A
2990328 Lincoln Jun 1961 A
3011949 Bilotti Dec 1961 A
3029189 Hardy, Jr. et al. Apr 1962 A
3047461 Hardy, Jr. et al. Jul 1962 A
3075884 Bilotti et al. Jan 1963 A
3196172 Wright, Jr. et al. Jul 1965 A
3308022 Cummings et al. Mar 1967 A
3498964 Hayashi et al. Mar 1970 A
3554767 Daum et al. Jan 1971 A
3590057 Suzuki et al. Jun 1971 A
3845217 Ferno et al. Oct 1974 A
3877468 Lichtneckert et al. Apr 1975 A
3894154 Graff et al. Jul 1975 A
3901248 Lichtneckert et al. Aug 1975 A
3995064 Ehrgott et al. Nov 1976 A
4150161 Rudolph et al. Apr 1979 A
4154814 Hand et al. May 1979 A
4156740 Glass et al. May 1979 A
4157402 Ogawa et al. Jun 1979 A
4223023 Furda Sep 1980 A
4238475 Witzel et al. Dec 1980 A
4238510 Cherukuri et al. Dec 1980 A
4250195 Cherukuri et al. Feb 1981 A
4250196 Friello Feb 1981 A
4283408 Hirata et al. Aug 1981 A
4292329 Ogawa et al. Sep 1981 A
4316915 Friello et al. Feb 1982 A
4317838 Cherukuri et al. Mar 1982 A
4372942 Cimiluca Feb 1983 A
4374858 Glass et al. Feb 1983 A
4378374 Reggio et al. Mar 1983 A
4386063 Boden May 1983 A
4386106 Merritt et al. May 1983 A
4400372 Muhler et al. Aug 1983 A
4446135 Fountaine May 1984 A
4452821 Gergely Jun 1984 A
4459311 DeTora et al. Jul 1984 A
4466983 Cifrese et al. Aug 1984 A
4474749 Kruppa Oct 1984 A
4496592 Kuwahara et al. Jan 1985 A
4512968 Komiyama et al. Apr 1985 A
4513012 Carroll et al. Apr 1985 A
4533556 Piccolo et al. Aug 1985 A
4555407 Kramer et al. Nov 1985 A
4563345 Arrick Jan 1986 A
4639368 Niazi et al. Jan 1987 A
4642235 Reed et al. Feb 1987 A
4647450 Peters et al. Mar 1987 A
4683138 Glass et al. Jul 1987 A
4711774 Denick, Jr. et al. Dec 1987 A
4716033 Denick, Jr. Dec 1987 A
4737366 Gergely et al. Apr 1988 A
4738850 Thakur et al. Apr 1988 A
4753800 Mozda Jun 1988 A
4753805 Cherukuri et al. Jun 1988 A
4755389 Jones et al. Jul 1988 A
4758424 Denick, Jr. et al. Jul 1988 A
4792453 Reed et al. Dec 1988 A
4822597 Faust et al. Apr 1989 A
4822816 Markham Apr 1989 A
4828820 Glass et al. May 1989 A
4832994 Fey May 1989 A
4835162 Abood May 1989 A
4849227 Cho Jul 1989 A
4853212 Faust et al. Aug 1989 A
4867989 Silva et al. Sep 1989 A
4882152 Yang et al. Nov 1989 A
4894234 Sharma et al. Jan 1990 A
4908211 Paz Mar 1990 A
4908212 Kwon et al. Mar 1990 A
4929447 Yang May 1990 A
4929508 Sharma et al. May 1990 A
4933184 Tsuk Jun 1990 A
4935242 Sharma et al. Jun 1990 A
4938963 Parnell Jul 1990 A
4944949 Story et al. Jul 1990 A
4963367 Ecanow Oct 1990 A
4963369 Song et al. Oct 1990 A
4968511 D'Amelia et al. Nov 1990 A
4968716 Markham Nov 1990 A
4971079 Talapin et al. Nov 1990 A
4971787 Cherukuri et al. Nov 1990 A
4971806 Cherukuri et al. Nov 1990 A
4975270 Kehoe Dec 1990 A
4975288 Hager et al. Dec 1990 A
4978537 Song Dec 1990 A
4980178 Cherukuri et al. Dec 1990 A
4997654 Corsello et al. Mar 1991 A
4997659 Yatka et al. Mar 1991 A
5013716 Cherukuri et al. May 1991 A
5015464 Strobridge May 1991 A
5045325 Lesko et al. Sep 1991 A
5070085 Markham Dec 1991 A
5077051 Gallopo et al. Dec 1991 A
5078460 Holsinger Jan 1992 A
5087460 Cherukuri et al. Feb 1992 A
5110608 Cherukuri et al. May 1992 A
5124156 Shibata et al. Jun 1992 A
5125819 Hager et al. Jun 1992 A
5126151 Bodor et al. Jun 1992 A
RE33988 Evans Jul 1992 E
5139787 Broderick et al. Aug 1992 A
5139794 Patel et al. Aug 1992 A
5154927 Song et al. Oct 1992 A
5156842 Mulligan Oct 1992 A
5179122 Greene et al. Jan 1993 A
5182099 Jonsson et al. Jan 1993 A
5229137 Wolfe Jul 1993 A
5244670 Upson et al. Sep 1993 A
5248508 Reed et al. Sep 1993 A
5284657 Lu et al. Feb 1994 A
5286500 Synosky et al. Feb 1994 A
5294433 Singer et al. Mar 1994 A
5294449 Greenberg Mar 1994 A
5324530 Kehoe et al. Jun 1994 A
5340566 Curtis et al. Aug 1994 A
5344659 Kurihara et al. Sep 1994 A
5378131 Greenberg Jan 1995 A
5380530 Hill Jan 1995 A
5380535 Geyer et al. Jan 1995 A
5397580 Song et al. Mar 1995 A
5409905 Eby, III Apr 1995 A
5410028 Asami et al. Apr 1995 A
5419919 Song et al. May 1995 A
5425961 Yatka et al. Jun 1995 A
5431929 Yatka et al. Jul 1995 A
5433960 Meyers Jul 1995 A
5445834 Burger et al. Aug 1995 A
5455286 Amidon et al. Oct 1995 A
5456677 Spector Oct 1995 A
5474989 Hashimoto et al. Dec 1995 A
5487902 Andersen et al. Jan 1996 A
5488962 Perfetti Feb 1996 A
5494685 Tyrpin et al. Feb 1996 A
5496541 Cutler Mar 1996 A
5498429 Orlandi Mar 1996 A
5512306 Carlsson et al. Apr 1996 A
5523097 Song et al. Jun 1996 A
5534272 Bernstein Jul 1996 A
5536511 Yatka Jul 1996 A
5543160 Song et al. Aug 1996 A
5554380 Cuca et al. Sep 1996 A
5569477 Nesbitt Oct 1996 A
5571528 Lee et al. Nov 1996 A
5571543 Song et al. Nov 1996 A
5576344 Sandler et al. Nov 1996 A
5578336 Monte Nov 1996 A
5580590 Hartman Dec 1996 A
5582855 Cherukuri et al. Dec 1996 A
5585110 Kalili et al. Dec 1996 A
5593685 Bye et al. Jan 1997 A
5601858 Mansukhani et al. Feb 1997 A
5605698 Ueno Feb 1997 A
5607697 Alkire et al. Mar 1997 A
5618517 Miskewitz Apr 1997 A
5628986 Sanker et al. May 1997 A
5629013 Upson et al. May 1997 A
5629026 Davis May 1997 A
5629035 Miskewitz May 1997 A
5637313 Chau et al. Jun 1997 A
5645853 Winston et al. Jul 1997 A
5651987 Fuisz Jul 1997 A
5656652 Davis Aug 1997 A
5665386 Benet et al. Sep 1997 A
5665406 Reed et al. Sep 1997 A
5667802 Grimberg Sep 1997 A
5670163 Cuca et al. Sep 1997 A
5693334 Miskewitz Dec 1997 A
5698215 Kalili et al. Dec 1997 A
5702687 Miskewitz Dec 1997 A
5711961 Reiner et al. Jan 1998 A
5716928 Benet et al. Feb 1998 A
5736175 Cea et al. Apr 1998 A
5744164 Chauffard et al. Apr 1998 A
5747475 Nordquist et al. May 1998 A
5753255 Chavkin et al. May 1998 A
5756074 Ascione et al. May 1998 A
5798101 Haveson Aug 1998 A
5800847 Song et al. Sep 1998 A
5824291 Howard Oct 1998 A
5827526 Dohnalek et al. Oct 1998 A
5830883 Block et al. Nov 1998 A
5834002 Athanikar Nov 1998 A
5846557 Eisenstadt et al. Dec 1998 A
5846952 Vournakis et al. Dec 1998 A
5854267 Berlin et al. Dec 1998 A
5858383 Precopio Jan 1999 A
5858391 Cuca et al. Jan 1999 A
5858412 Staniforth et al. Jan 1999 A
5858413 Jettka et al. Jan 1999 A
5858423 Yajima et al. Jan 1999 A
5866179 Testa Feb 1999 A
5877173 Olney et al. Mar 1999 A
5880109 Nakamura et al. Mar 1999 A
5882702 Abdel-Malik et al. Mar 1999 A
5885630 Zurawski et al. Mar 1999 A
5885992 Ohgi et al. Mar 1999 A
5889028 Sandborn et al. Mar 1999 A
5889029 Rolf Mar 1999 A
5891422 Pan et al. Apr 1999 A
5897891 Godfrey Apr 1999 A
5900230 Cutler May 1999 A
5910308 D'Jang Jun 1999 A
5912007 Pan et al. Jun 1999 A
5912030 Huzinec et al. Jun 1999 A
5916606 Record et al. Jun 1999 A
5922346 Hersh Jul 1999 A
5922347 Hausler et al. Jul 1999 A
5928664 Yang et al. Jul 1999 A
5945107 Hessel et al. Aug 1999 A
5958380 Winston et al. Sep 1999 A
5958472 Robinson et al. Sep 1999 A
5980955 Greenberg et al. Nov 1999 A
5989588 Korn et al. Nov 1999 A
6024988 Ream et al. Feb 2000 A
6066342 Gurol et al. May 2000 A
6077524 Bolder et al. Jun 2000 A
6090412 Hashimoto et al. Jul 2000 A
6139872 Walsh Oct 2000 A
6165516 Gudas et al. Dec 2000 A
6200604 Pather et al. Mar 2001 B1
6224872 Shibuya et al. May 2001 B1
6242019 Bell et al. Jun 2001 B1
6248378 Ganan-Calvo Jun 2001 B1
6280762 Bealin-Kelly et al. Aug 2001 B1
6290985 Ream et al. Sep 2001 B2
6350480 Urnezis et al. Feb 2002 B1
6491540 Barreca Dec 2002 B1
6586023 Song et al. Jul 2003 B1
6627234 Johnson et al. Sep 2003 B1
6652839 Barreca Nov 2003 B2
6773716 Ream et al. Aug 2004 B2
6869614 Barreca Mar 2005 B2
6872410 Soldani et al. Mar 2005 B2
6949264 McGrew et al. Sep 2005 B1
7163705 Johnson et al. Jan 2007 B2
7351425 Barreca Apr 2008 B2
7612045 Eldridge Nov 2009 B2
8202561 Livaich Jun 2012 B2
8679522 Barreca Mar 2014 B2
20020110581 Ream et al. Aug 2002 A1
20020127189 Myers et al. Sep 2002 A1
20020159956 Ream et al. Oct 2002 A1
20030138518 Kiefer et al. Jul 2003 A1
20040247669 Gin et al. Dec 2004 A1
20050002992 McCleary et al. Jan 2005 A1
20050048164 Stahl Mar 2005 A1
20060062863 Ghosal Mar 2006 A1
20070123448 Kaplan et al. May 2007 A1
20090143279 Mootha et al. Jun 2009 A1
20120177730 Baron et al. Jul 2012 A1
20130095140 Baron et al. Apr 2013 A1
20130115329 Savant et al. May 2013 A1
20130177604 Baron et al. Jul 2013 A1
20140030332 Baron et al. Jan 2014 A1
Foreign Referenced Citations (4)
Number Date Country
WO 9818339 May 1998 WO
WO 9823165 Jun 1998 WO
WO 0006127 Feb 2000 WO
WO 2014022772 Feb 2014 WO
Non-Patent Literature Citations (15)
Entry
U.S. Appl. No. 14/220,224, filed Mar. 20, 2014, Barreca.
The Food Channel newsletter, Aug. 30, 1996, vol. 8, No. 16.
The Sydney Morning Herald, “Smarter up your act,” Sep. 11, 1999, 4 pages.
On-line Medical Dictionary definition of “taurine”, Published at the Dept. of Medical Oncology, University of Newcastle upon Tyne, Copyright 1997-2004—The CancerWEB Project. Retrieved from: http://cancerweb.ncl.ac.uk/cgi-bin/omd?taurine.
“Guaraná,” Tropical Plant Database, Raintree Nutrition, Inc., 1996-2003, (preprinted from Herbal Secrets of the Rainforest, 2nd edition, by Leslie Taylor, Sage Press, Inc., 2003). Retrieved from: http//www.rain.tree.com/guarana.htm.
Arellano, “More Amore? Herbal Gum Makers Cater to Natural Urges”, Detroit Free Press, Mar. 29, 1994.
Chaplin, “Water Activity,” updated Dec. 21, 2003, 4 pages. Retrieved from: www1.lsbu.ac.uk/water/.
Harrison et al., “Ginseng,” Alternative Field Crops Manual, 1992, (updated Jan. 26, 2000), 8 pages.
Horovitz, “Sticky business Ptooie! Gum on the outs with U.S. chewers”, USA Today, Jul. 16, 1998.
Miura et al. “Effect of guarana on exercise in normal and epinephrine-induced glycogenolytic mice”; Biol PHarm Bull, Jun. 1998 21(6)646-8.
Morton JF. “Widespread tannin intake via stimulants and masticatories, especially guarana, kola nut, betel vine, and accessorires”; Basic Life Sci 1992; 59:739-65.
Sato et al., “On Drowsiness Preventive Gum that Contains Guarana Extract”, 1988, pp. 1-11.
Sloan, Elizabeth A., “The Ten Top Functional Food Trends”, Food Technology, vol. 54, No. 4, Apr. 2000.
Printout of Herbalife “NRG” Gum (known as “Chew Slim Gum”, 1992, 4 pages.
Doyle et al., “Systems-based Disclovery of Tomatidine as a Natural Small Molecule Inhibitor of Skeletal Muscle Atrophy,” J. Biol. Chem., 2014, vol. 289(21), pp. 1491-1424.
Related Publications (1)
Number Date Country
20140294915 A1 Oct 2014 US
Provisional Applications (1)
Number Date Country
60154972 Sep 1999 US
Continuations (4)
Number Date Country
Parent 11084707 Mar 2005 US
Child 12052054 US
Parent 10646503 Aug 2003 US
Child 11084707 US
Parent 10316700 Dec 2002 US
Child 10646503 US
Parent 09664630 Sep 2000 US
Child 10316700 US
Continuation in Parts (2)
Number Date Country
Parent 14220224 Mar 2014 US
Child 14283459 US
Parent 12052054 Mar 2008 US
Child 14220224 US